Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2012

View Archived Issues

Phase II ALS trial set to begin with fingolimod

Self-propelled microrockets with drug delivery potential function in acidic environments

Exelixis synthesizes lysophospholipid S1P1 receptor antagonists with antitumor potential

China Medical University presents new sodium/iodide cotransporter proteins

Nippon Chemiphar patents novel P2X4 receptor antagonists

Russian team patents novel interferon alfa-2b conjugates

Japanese researchers present new protein kinase inhibitors

Dako and Amgen begin new collaboration

CHMP issues opinion on Humira in ulcerative colitis

Fuso Pharmaceutical synthesizes new agents to treat cancer

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized by Sanofi

EMA adopts scientific opinion on Pyramax

Pivotal Takeda trial meets primary endpoints

Studies clarify genetic basis of Bartsocas-Papas syndrome

Critical Pharma and U.K. university team up to develop nasal spray for osteoporosis

FDA accepts Actemra sBLA for review

Genticel completes recruitment in phase Ib trial of HPV vaccine

Redevant launched in Mexico

GSK exercises exclusive license option for compounds developed with Galapagos

CHMP requests additional information on Glybera

Amsterdam Molecular Therapeutics' assets and liabilities to be acquired by uniQure

Threshold Pharmaceuticals' phase IIb study in pancreatic cancer meets primary endpoint

Novel inhibitor of V600-mutant B-raf shows antitumor activity in animal models

UMN Pharma licenses novel norovirus and rotavirus combination vaccine candidate

FDA places clinical hold on Capesaris

Innocoll announces successful end-of-phase II meeting with FDA for XaraColl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...